Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

03. Juni 2013 09:01 ET | Quelle: Repros Therapeutics Inc.

Repros to Webcast Investor and Analyst Day on June 6th

THE WOODLANDS, Texas, June 3, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it will host a live webcast of its Investor and Analyst Day that is being held...
22. Mai 2013 20:01 ET | Quelle: Repros Therapeutics Inc.

FDA Recommends Running Phase 2b Trial of Proellex(R)-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids

THE WOODLANDS, Texas, May 22, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has met with the FDA regarding the clinical development of Proellex-V, the...
10. Mai 2013 09:25 ET | Quelle: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial Results

THE WOODLANDS, Texas, May 10, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the first quarter ended March 31, 2013. Liquidity and...
02. Mai 2013 12:59 ET | Quelle: Repros Therapeutics Inc.

Repros Reports Second Pivotal Androxal(R) Study Fully Enrolled Ahead of Schedule

THE WOODLANDS, Texas, May 2, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has fully enrolled the 180 subject second pivotal study (ZA-302) for...
29. April 2013 12:00 ET | Quelle: Repros Therapeutics Inc.

Repros' Proellex(R) in Breast Cancer Phase 2 Study in Collaboration With Northwestern University

THE WOODLANDS, Texas, April 29, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) announced it is collaborating with Feinberg School of Medicine and the Breast Cancer Program at...
29. April 2013 11:32 ET | Quelle: Repros Therapeutics Inc.

Repros to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

Company to Webcast Presentation on May 16, 2013 THE WOODLANDS, Texas, April 29, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that Joseph S. Podolski,...
10. April 2013 12:22 ET | Quelle: Repros Therapeutics Inc.

Repros Reports Issuance of Two Additional U.S. Androxal(R) Patents

Both patents cover the significant co-morbidity associated with low T and Type 2 diabetes US patents 8,372,887 and 8,377,991 will expire in 2028 and 2031, respectively THE WOODLANDS,...
27. März 2013 20:01 ET | Quelle: Repros Therapeutics Inc.

Repros Reports Both Primary Endpoints Successfully Met in First Pivotal Study of Androxal(R)

79-83% in normal testosterone (T) range (FDA requirement 75%) No patient elevated beyond normal range Androxal's impact on sperm concentration meets FDA non-inferiority threshold compared...
25. März 2013 10:03 ET | Quelle: Repros Therapeutics Inc.

American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study for Podium Presentation at Annual Meeting

Abstract Title: Evaluation of Enclomiphene (Androxal®) and Testim® on Testosterone (T), Pituitary Hormones and Sperm Function Presenters: Dr. John Dean (Past President...
18. März 2013 09:25 ET | Quelle: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2012 Financial Results

THE WOODLANDS, Texas, March 18, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the quarter and year ended December 31, 2012. Liquidity...

Vorherige Seite

Nächste Seite